Go Pro

Kalaris Therapeutics (KLRS) Earnings Date, Estimates & Call Transcripts

Kalaris Therapeutics logo
$3.92 -0.04 (-0.91%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kalaris Therapeutics Earnings Summary

Kalaris Therapeutics issued Q2 2026 earnings on August 11, 2026, reporting an EPS of -$0.48, which topped the consensus estimate of -$0.50 by $0.02. With a trailing EPS of -$2.02, Kalaris Therapeutics' earnings are expected to remain at ($1.99) per share in the coming year.

Q2 2026 Earnings Resources

Consensus EPS
(Aug. 11)
-$0.50
Actual EPS
(Aug. 11)
-$0.48 Beat By $0.02
Get Kalaris Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kalaris Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

KLRS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Kalaris Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.57-$0.57-$0.57
Q2 20261-$0.57-$0.57-$0.57
Q3 20261-$0.60-$0.60-$0.60
Q4 20261-$0.58-$0.58-$0.58

Kalaris Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026-$0.50-$0.48+$0.02-$0.48--
5/12/2026Q1 2026-$0.52-$0.46+$0.06-$0.46--
3/17/2026Q4 2025-$0.56-$0.44+$0.12-$0.44--
11/12/2025Q3 2025-$0.66-$0.64+$0.02-$0.64--
8/13/2025Q2 2025-$0.51-$0.61 -$0.10-$0.61--

Kalaris Therapeutics Earnings - Frequently Asked Questions

Kalaris Therapeutics (NASDAQ:KLRS) last announced its quarterly earning data on Tuesday, August 11, 2026. Learn more on KLRS's earnings history.

In the previous quarter, Kalaris Therapeutics (NASDAQ:KLRS) reported ($0.48) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.50) by $0.02. Learn more on analysts' earnings estimate vs. KLRS's actual earnings.

Kalaris Therapeutics (NASDAQ:KLRS) has a recorded net income of -$43.44 million. KLRS has generated -$2.02 earnings per share over the last four quarters.

Kalaris Therapeutics' earnings are expected to stay at ($1.99) per share in the next year.


Earnings data for NASDAQ:KLRS is sourced from Fiscal.ai, with the most recent quarter reported on 8/11/2026. New results are added as companies report their earnings.
From Our Partners